Medtronic plc
Medtronic PLC Announces Issuance of Senior Notes and Redemption of Outstanding Notes
Summary
On September 29, 2025, Medtronic PLC, through its subsidiary Medtronic, Inc., issued €1.5 billion aggregate principal amount of senior notes due 2030 and 2045, and Medtronic Luxco redeemed all €500 million of its outstanding 2.625% Senior Notes due 2025. The new notes will be used to repay existing senior notes.
Profitelligence Alerts
Get alerts for MDT
Be first to know when Medtronic plc files with the SEC.
Filing Categories
Advertisement
About Medtronic plc
Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.
Official SEC Documents
Advertisement